NewAmsterdam Pharma Sees Unusually Large Options Volume (NASDAQ:NAMS)

NewAmsterdam Pharma logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Call-option trading surged: Traders bought 7,505 NAMS call options on Tuesday, about 962% above the typical volume of 707.
  • Shares were under pressure: The stock closed at $19.39, near its 12-month low of $17.90. NewAmsterdam reported a quarterly loss of $0.14 per share, better than the $0.47 loss analysts expected, and revenue of $19.16 million versus an $8.82 million estimate.
  • Analyst sentiment remained broadly positive: The consensus rating was “Moderate Buy,” with an average price target of $49.82. Insiders sold 176,846 shares worth about $4.66 million over the prior 90 days, although CEO Michael Davidson also purchased 10,000 shares.
  • Five stocks we like better than NewAmsterdam Pharma.

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) saw some unusual options trading on Tuesday. Traders acquired 7,505 call options on the company. This is an increase of approximately 962% compared to the typical volume of 707 call options.

Insider Activity at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, insider Johannes Kastelein sold 125,000 shares of NewAmsterdam Pharma stock in a transaction on Monday, August 24th. The stock was sold at an average price of $26.91, for a total transaction of $3,363,750.00. Following the completion of the transaction, the insider owned 69,302 shares in the company, valued at approximately $1,864,916.82. The trade was a 64.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Michael Davidson bought 10,000 shares of the company's stock in a transaction on Monday, September 14th. The stock was bought at an average cost of $22.65 per share, for a total transaction of $226,500.00. Following the completion of the acquisition, the chief executive officer directly owned 792,923 shares of the company's stock, valued at approximately $17,959,705.95. This represents a 1.28% increase in their position. The SEC filing for this purchase provides additional information. Insiders sold a total of 176,846 shares of company stock valued at $4,661,919 in the last 90 days. Corporate insiders own 12.74% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Parallel Advisors LLC boosted its holdings in NewAmsterdam Pharma by 43.7% in the third quarter. Parallel Advisors LLC now owns 2,012 shares of the company's stock worth $49,000 after purchasing an additional 612 shares during the last quarter. AlphaCentric Advisors LLC raised its stake in NewAmsterdam Pharma by 4.6% during the 3rd quarter. AlphaCentric Advisors LLC now owns 15,549 shares of the company's stock valued at $378,000 after buying an additional 681 shares during the last quarter. KBC Group NV purchased a new stake in NewAmsterdam Pharma during the 1st quarter valued at $37,000. Kornitzer Capital Management Inc. KS raised its stake in NewAmsterdam Pharma by 1.3% during the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 141,711 shares of the company's stock valued at $3,446,000 after buying an additional 1,778 shares during the last quarter. Finally, Arizona State Retirement System lifted its holdings in shares of NewAmsterdam Pharma by 34.6% during the 2nd quarter. Arizona State Retirement System now owns 16,656 shares of the company's stock valued at $564,000 after buying an additional 4,281 shares during the period. Institutional investors own 89.89% of the company's stock.

NewAmsterdam Pharma Price Performance

NASDAQ NAMS traded down $0.07 during trading hours on Tuesday, hitting $19.39. The company's stock had a trading volume of 1,364,098 shares, compared to its average volume of 1,207,235. NewAmsterdam Pharma has a 12 month low of $17.90 and a 12 month high of $42.21. The company's 50 day simple moving average is $21.41 and its two-hundred day simple moving average is $29.12. The company has a market cap of $2.33 billion, a P/E ratio of -11.47 and a beta of 0.15.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.47) by $0.33. NewAmsterdam Pharma had a negative net margin of 789.95% and a negative return on equity of 31.39%. The firm had revenue of $19.16 million for the quarter, compared to the consensus estimate of $8.82 million. As a group, research analysts predict that NewAmsterdam Pharma will post -1.48 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Wall Street Zen raised shares of NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a research report on Sunday, November 1st. Royal Bank Of Canada reduced their price objective on shares of NewAmsterdam Pharma from $50.00 to $42.00 and set an "outperform" rating for the company in a research note on Monday, October 5th. Needham & Company LLC decreased their target price on shares of NewAmsterdam Pharma from $48.00 to $46.00 and set a "buy" rating for the company in a report on Thursday, November 5th. BMO Capital Markets started coverage on shares of NewAmsterdam Pharma in a research note on Monday, July 20th. They issued an "outperform" rating and a $58.00 target price on the stock. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of NewAmsterdam Pharma in a report on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $49.82.

View Our Latest Analysis on NewAmsterdam Pharma

NewAmsterdam Pharma Company Profile

(Get Free Report)

NewAmsterdam Pharma is a biopharmaceutical company focused on developing oral treatments for cardiometabolic diseases, particularly conditions involving elevated cholesterol and cardiovascular risk. The company's lead investigational medicine is obicetrapib, an oral inhibitor of cholesteryl ester transfer protein (CETP) being studied to lower LDL cholesterol. NewAmsterdam has evaluated obicetrapib both on its own and in combination with ezetimibe, including in clinical studies involving people with inherited high cholesterol or established cardiovascular disease whose cholesterol remains elevated despite existing treatment.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in NewAmsterdam Pharma Right Now?

Before you consider NewAmsterdam Pharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NewAmsterdam Pharma wasn't on the list.

While NewAmsterdam Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines